ZMIZ2

Across TCGA pan-cancer cohorts, ZMIZ2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZMIZ2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ZMIZ2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZMIZ2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

CHOL, STAD, and PAAD are the cancer types where ZMIZ2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
STAD	OS	Median	IV	0.001	0.544	<.001	30	view →
PAAD	OS	Median	All	0.062	0.647	<.001	21	view →
UCEC	DFS	Median	All	1.000	0.631	.010	16	view →
COAD	OS	Median	III,IV	0.133	0.783	<.001	15	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →
LUAD	DFS	Median	All	1.000	0.335	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZMIZ2–CHOL (OS)

Open the CHOL breakdown →